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Objectives: Sinusoidal injury (SI) after oxaliplatin-based therapies for colorectal liver metastasis (CRLM)
can increase postoperative morbidity. Preoperative methods to estimate SI are lacking. The aim of this
study was to identify SI by evaluating portal vein haemodynamics.
Methods: Magnetic resonance imaging flowmetry (MRIF) was used to estimate portal vein haemody-
namics in 29 patients with CRLM before liver surgery. Sinusoidal injury was evaluated from resected
non-tumorous liver parenchyma according to the combined vascular injury (CVI) score of 3.
Results: All patients with SI (six of 29) received oxaliplatin; however, a significant association could not
be proven (P = 0.148). Oxaliplatin-treated patients showed portal vein dilatation in both the SI and non-SI
groups compared with patients who had not received oxaliplatin (Bonferroni corrected P = 0.003 and
P = 0.039, respectively). Mean portal velocity tended to be lower in patients with SI compared with
oxaliplatin-treated patients without SI (Bonferroni corrected P = 0.087). A mean portal velocity of
14.35 cm/s together with a cross-section area of 1.55 cm2 was found to predict SI with sensitivity of
100% and specificity of 78%.
Conclusions: Oxaliplatin treatment was associated with portal vein dilatation. Patients with SI showed
a tendency towards decreased mean portal flow velocity. This may indicate that SI is associated with an
increased resistance to blood flow in the liver parenchyma. Portal vein haemodynamic variables
estimated by MRIF can identify patients without SI non-invasively.
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Introduction
During the last decade, the introduction of new chemotherapeutic
agents has altered themanagement of patients with colorectal liver
metastasis (CRLM). At present, approximately 70% of CRLM
patients at Uppsala University Hospital receive neoadjuvant che-
motherapy prior to liver surgery. Oxaliplatin- or irinotecan-based
chemotherapies increase resectability rates by downsizing initially
non-resectable tumours and provide overall survival benefits after
liver surgery.1 In patients with resectable CRLM, neoadjuvant che-
motherapy increases disease-free survival2 and probably allows for
the identification and selection of patients with favourable tumour
biology.3 Neoadjuvant chemotherapy can induce a complete
radiological response, which is unfavourable when localizing
tumours perioperatively,4 and also has various adverse effects on
the liver parenchyma. Irinotecan is associated with chemotherapy-
associated steatohepatitis and increased postoperative mortality
caused by liver failure.5 Oxaliplatin has been reported to cause
sinusoidal injury (SI) in 5–50% of patients.6–8 Sinusoidal injury is
associatedwith a higher need for perioperative blood transfusions9
and increased postoperative morbidity,10,11 and may have a nega-
tive impact on longterm prognosis.12 However, other studies have
not been able to show an increase in postoperative morbidity or
mortality after oxaliplatin-based chemotherapy.13
Several studies have attempted to identify predictive factors for
SI.14–18 A non-invasive and accurate assessment for SI is lacking.
Preoperative biopsy of liver parenchyma is invasive and is not
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recommended because the amounts of tissue achieved are small
and sampling error is possible.19 Studies of SI are usually based on
non-tumorous liver tissue derived from resection.7,8 Intra- and
interobserver variation can be minimized by using a semi-
quantitative scoring system for combined vascular injury (CVI).8
Laboratory parameters such as a gamma-glutamyl transpeptidase
(GGT) level that is > 1.5 times higher than the normal range14 or
an aspartate aminotransferase to platelet ratio index (APRI) that
is > 0.3617 can be used to predict SI preoperatively. Increased
spleen size has been reported after oxaliplatin-based therapy20 and
patients with an increase in spleen size of >50% have been
reported to be at high risk for SI.16 The hypothesis that oxaliplatin-
induced SI can lead to portal hypertension and subsequently sple-
nomegaly and thrombocytopoenia has been proposed.21 Two
case reports showed that oxaliplatin-based chemotherapy might
induce significant portal hypertension as verified by direct
measurement of portal venous pressure.21,22 Portal flow haemody-
namics can also be evaluated non-invasively using Doppler ultra-
sonography or magnetic resonance imaging flowmetry (MRIF).23
Superparamagnetic iron oxide-enhanced MRI has been used to
evaluate liver parenchyma for sinusoidal changes.15,18
The aim of the present study was to investigate whether portal
vein haemodynamics as measured by MRIF were changed in
patients with SI or in patients who had undergone oxaliplatin-
based treatment for CRLM. A secondary aim was to evaluate
preoperative MRIF as a predictive tool for SI.
Materials and methods
Patients
All patients scheduled for CRLM resection at the study institution
were prospectively evaluated during 2007–2009. The principal
inclusion criterion was a planned minimum two-segment resec-
tion in order to derive a sufficient amount of non-tumorous liver
tissue for histopathology. Exclusion criteria included the presence
of general contraindications to MRI. All patients who met the
inclusion criteria and provided written informed consent were
included in the study, provided the MRI facility was available.
Patients were examined by MRIF 1 day prior to planned liver
surgery. Preoperative blood tests and liver function tests were
conducted routinely. The study was approved by the regional
ethics committee (protocol no. 2007/020). The study cohort was a
subgroup of patients reported in an earlier study by this group on
liver steatosis and steatohepatitis prediction by proton magnetic
resonance spectroscopy.24
Magnetic resonance imaging flowmetry
Magnetic resonance imaging flowmetry was measured using a
3T Achieva MRI scanner (Philips Medical Systems Nederland
BV, Best, the Netherlands) using the SENSE-CARDIAC coil, with
the patient in a supine position under basal fasting conditions.
Axial and coronal steady-state free precession images of the
portal venous system were used to establish the correct orienta-
tion of the oblique section required for flow measurements. The
axial and coronal (in parenthesis) localizer images were taken at
a repetition time of 2.5 ms (2.6 ms), an echo time of 1.2 ms
(1.3 ms), a matrix size of 275 ¥ 288 (217 ¥ 320), a field of view
of 40 cm (45 cm) and a flip angle of 40 °. These localizing
images were acquired in 15 s (10 s). Cine phase-contrast (CPC)
imaging was performed during a breath hold using triggering by
vector electrocardiogram. The oblique CPC image used for flow
calculations was oriented perpendicular to flow in the main
portal vein before bifurcation to the left and right portal
branches. Acquisition was taken with a repetition time 5.6 ms, an
echo time of 3.6 ms, a flip angle of 10 °, a velocity encoding of
50 cm/s, a matrix size of 112 ¥ 256 and a field of view of 30 cm.
The number of signal averages was two, and section thickness
was 6 mm. Flow encoding was selected parallel with the direc-
tion of blood flow. Acquisition time was 18 s. Using scanner-
associated software (Philips Medical Systems Nederland BV),
CPC flow rates were calculated by integrating the velocity
product of 17 velocity images spanning the cardiac cycles.
Regions of interest encompassing the portal vein cross-section
areas were manually placed on the oblique CPC images. Mean
flow rates were derived from the average flow rate during each
phase of the cardiac cycle; portal flow, cross-section area, mean
and peak velocities were calculated. These processes were per-
formed by a radiologist blinded to clinical and histopathological
data.
Histopathology
Non-tumorous liver specimens were obtained from the resected
portion of the liver directly after surgery. Effort was made to
retrieve parenchymal blocks measuring approximately 40 ¥ 40 ¥
7 mm, avoiding big vessels and large bile duct structures, at
20 mm from the peritoneal liver surface, the resection margin
and themetastases. The samples were directly fixed in 10% neutral
buffered formalin (4% formaldehyde), embedded in paraffin
blocks, cut into thicknesses of 3 mm and stained with haematoxy-
lin and eosin, van Gieson and Gordon–Sweets reticulin stains. For
immunohistochemical stainings, the sections were heated in Tris
EDTA buffer, pH 9 (S2367; Dako Denmark A/S, Glostrup,
Denmark) in a microwave oven for 10 min at 750 W followed by
15 min at 350 W for antigen retrieval. Tissue sections were stained
by immunohistochemistry or immunofluorescence techniques
with antibodies against ki-67 (clone MIB-1; Dako Denmark A/S)
(ready to use: IR626). Antibody detection was performed using
the REAL Envision Peroxidase DAB Detection System (Dako
Denmark A/S) and haematoxylin was used for counterstaining.
Figure 1 shows example findings in stained tissue.All liver samples
were evaluated by an experienced liver pathologist blinded to
clinical and MRIF data. Sinusoidal injury was graded according to
CVI score (Table 1), for which the minimum and maximum
number of points were 0 and 13, respectively. A CVI score of 3
was recognized as indicative of clinically relevant SI.8 Fibrosis
stages were assessed using the scoring system described by Kleiner
et al. (0–4 points).25
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Statistical analysis
Quantitative variables were expressed as the median and inter-
quartile range (IQR). Summary statistics were compared in
univariate analysis using Fisher’s exact test,Mann–Whitney test or
Kruskal–Wallis test as appropriate.P-values derived frommultiple
comparison tests were adjusted according to Bonferroni correc-
tion.Associations between quantitative variables were tested using
Spearman correlations. All data were analysed using IBM® SPSS®
Statistics Version 20 (IBM Corp., Armonk, NY, USA). The receiver
operating characteristic (ROC) method was used to evaluate hae-
modynamic variables and their combinations in a predictive
model associated with SI by calculating the area under the ROC
curve, sensitivity, specificity and their 95% confidence intervals
(CIs) using R software Version 2.14.1 [R Foundation for Statistical
Computing (http://www.r-project.org/)]. A two-sided P-value of
<0.05 was considered to indicate statistical significance.
Results
Patients and clinical data
During the study period, 105 patients were scheduled for CRLM
resection. The number of patients included was mostly restricted
by limits to access to the MRI facility for research purposes. Thirty
patients were not eligible because their planned liver resections
were small and three patients were excluded for contraindications
to MRI. A total of 33 patients were examined by MRIF and 30
fulfilled the MRI protocol. Appropriate liver tissue samples were
obtained in 29 patients (20 male, nine female) and were analysed
in the study. The most important clinical characteristics of these
patients are demonstrated in Table 2. Three patients had diabetes
(a)
(b)
Figure 1 Histopathological findings in a patient with sinusoidal injury
in addition to sinusoidal dilatation. (a) An extensive parenchymal
extinction lesion (PEL) (black arrow) is seen in non-tumorous paren-
chyma. The border between the normal liver parenchyma and PEL is
characterized by hepatocyte plate disruption. In addition, a small
area with steatosis can be seen. (Van Gieson stain; original magni-
fication ¥4.) (b) Immunohistochemical staining for ki-67 was utilized
to judge cases with suspicious nodular regenerative hyperplasia.
Groups of smaller hepatocytes positive for ki-67 confirmed the pres-
ence of a focus of subtle nodular regenerative hyperplasia. (Original
magnification ¥20)
Table 1 Criteria used to derive a combined vascular injury score
(0–13)8
Histopathological feature Score
Diffuse sinusoidal dilation
None 0
<1/3 of a lobule 1
1/3–2/3 of a lobule 2
Entire lobule 3
Small vessel loss/obliteration
None 0
<1/3 of vessels 1
1/3–2/3 of vessels 2
>2/3 of vessels 3
Focal hepatocyte plate disruption
None 0
Present 1
Parenchymal extinction lesion
None 0
Rare 1
Frequent 2
Nodular regenerative hyperplasia
None 0
Subtle 1
Obvious 2
Peliosis
None 0
Present 1
Veno-occlusive disease-like change
None 0
Present 1
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mellitus. A total of 21 patients had received oxaliplatin-based
chemotherapy, seven had received irinotecan-based chemo-
therapy, mostly in combination with 5-fluorouracil/leucovorin
(FLV) or Xeloda, and two patients had received FLV alone. Five
patients had received no chemotherapy.
Surgeries included 23 major resections (more than three seg-
ments) and six resections of two segments. No mortality was
observed within 90 days of surgery.Morbidity defined as a Clavien
score26 of 3b was observed in four of 29 patients and consisted
of biliary leakages (n = 2), liver failure (n = 1) and haemorrhage
(n = 1).
Histopathology
Histopathological analysis observed SI defined as a CVI score of
3 (Table 1) in six of 29 patients. The median CVI score in the
group of patients with SI was 5 (IQR: 4–6). Twenty patients had
no fibrosis at all. The remaining nine patients had zone 3 perisi-
nusoidal fibrosis that was mild (n = 8) (stage 1a) or moderate (n =
1) (stage 1b). All patients with SI had received oxaliplatin-based
chemotherapy; however, Fisher’s exact test failed to prove a sig-
nificant association (P = 0.148). In order to make further com-
parisons, three groups of patients were defined as, respectively:
patients who had not received oxaliplatin-based chemotherapy
(no-OX); patients who had received oxaliplatin-based therapy
without SI (OX + no-SI), and patients who had received
oxaliplatin-based therapy with SI (OX + SI) (Tables 2 and 3).
Patients who had not received oxaliplatin-based chemotherapy
were older than those treated with oxaliplatin (P = 0.044) as a
result of selection prior to treatment.
Blood tests
All patients underwent routine blood tests [aspartate aminotrans-
ferase (AST), alanine aminotransferase, alkaline phosphatase,
bilirubin, prothrombin time and platelet count] in which results
were found to be within the normal reference intervals the day
before surgery. Prothrombin time showed a statistically significant
(P = 0.040) but clinically unimportant difference in distribution
among the groups but remained within the normal reference
interval. A trend towards a decreased platelet count (P = 0.064)
was observed across the groups; however, this parameter also
remained within the normal reference interval (Table 2).
Portal vein haemodynamics as measured by MRIF
The portal vein cross-section area differed significantly among the
groups (P = 0.005) (Table 3). Portal vein dilatation was observed
in the OX + SI group (Bonferroni corrected P = 0.003) and
Table 2 Clinical characteristics of patients in the three study groups defined according to whether or not patients received oxaliplatin-based
chemotherapy and experienced sinusoidal injury
Characteristic All (n = 29) No-OX (n = 8) OX + no-SI (n = 15) OX + SI (n = 6) P-valuea
Age, years, median (IQR) 62 (56–71) 73 (61–77) 59 (55–66) 57 (55–63) 0.044
Body mass index, kg/m2, median (IQR) 27.2 (25.1–29.8) 27.8 (24.2–37.4) 27.8 (26.0–30.0) 25.9 (23.7–27.3) 0.270
Synchronous CRLM, n 16 2 9 5 0.082
Number of tumours, median (IQR) 2 (1–3) 1 (1–3) 2 (1–4) 3 (1–6) 0.209
Maximal tumour diameter, mm, median (IQR) 25 (19–50) 23 (20–54) 25 (20–49) 20 (10–60) 0.687
Platelet count, ¥109/l, median (IQR) 236 (203–270) 257 (224–308) 237 (200–281) 206 (190–212) 0.064
Number of OX cycles, median (IQR) 5 (4–7) – 5 (4–7) 6 (4–7) 0.843
Interval between OX treatment and surgery,
weeks, median (IQR)
6 (4–34) – 6 (4–29) 18 (4–109) 0.613
aKruskal–Wallis test was used to compare the distributions of continuous variables and the chi-squared test was used to compare nominal variables
among the three groups.
No-OX, patients who did not receive oxaliplatin-based chemotherapy; OX + no-SI, patients who received oxaliplatin-based chemotherapy without
sinusoidal injury; OX + SI, patients who received oxaliplatin-based chemotherapy with sinusoidal injury; IQR, interquartile range; CRLM, colorectal liver
metastasis.
Table 3 Results of magnetic resonance imaging flowmetry in the three study groups defined according to whether or not patients received
oxaliplatin-based chemotherapy and experienced sinusoidal injury
Characteristic All (n = 29) No-OX (n = 8) OX + no-SI (n = 15) OX + SI (n = 6) P-valuea
Portal flow, ml/s, median (IQR) 17.9 (13.5–20.8) 15.5 (11.0–19.1) 19.6 (16.2–21.3) 19.8 (14.8–23.2) 0.241
Cross-section area, cm2, median (IQR) 1.5 (1.2–1.8) 1.2 (0.9–1.2) 1.7 (1.2–2.0) 1.7 (1.6–2.1) 0.005
Mean velocity, cm/s, median (IQR) 14.0 (12.2–16.3) 16.3 (13.4–18.5) 14.3 (12.7–17.4) 12.0 (10.2–13.5) 0.060
Peak velocity, cm/s, median (IQR) 23.2 (19.9–26.6) 25.5 (20.3–29.3) 24.3 (21.4–26.5) 19.6 (18.2–26.4) 0.311
aKruskal–Wallis test was used to compare distributions among the three groups.
No-OX, patients who did not receive oxaliplatin-based chemotherapy; OX + no-SI, patients who received oxaliplatin-based chemotherapy without
sinusoidal injury; OX + SI, patients who received oxaliplatin-based chemotherapy with sinusoidal injury; IQR, interquartile range.
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the OX + no-SI group (Bonferroni corrected P = 0.039) compared
with the no-OX group. However, no difference was observed
between the OX + SI and OX + no-SI groups (Fig. 2).
Mean portal vein blood flow velocity showed a tendency to
differ among the groups (P = 0.060). The OX + SI group showed
a tendency towards a decreasedmean flow velocity compared with
the OX + no-SI group (Bonferroni corrected P = 0.087) (Fig. 2).
No differences between the OX + no-SI and OX + SI groups
compared with the no-OX group were observed (Bonferroni cor-
rected P = 1.000 and P = 0.129, respectively).
Portal blood flow and peak portal blood flow velocity did not
differ among the groups (P = 0.241 and P = 0.311, respectively).
No significant correlation was observed between fasting time
and measured haemodynamic variables although fasting time
varied among patients with median 6.5 h (IQR: 4.9–8.0 h).
Diagnostic accuracy of MRIF
The diagnostic accuracy of MRIF was evaluated in all patients
with CVI scores of 3 and < 3, respectively, because the present
data were unable to show a significant association between
oxaliplatin-based treatment and SI. The ROC method identified
best discriminating threshold values for haemodynamic variables
(Table 4). The combination of mean flow velocity and cross-
section area used in the SI prediction model (Fig. 3) showed the
highest discriminative ability according to the area under the ROC
curve, but the present data were unable to demonstrate significant
differences in performance among variables and their combina-
tions. According to this model, in patients with a mean flow veloc-
ity of 14.35 cm/s and a cross-section area of 1.55 cm2,
sensitivity was 100%, specificity reached 78%, the positive predic-
tive value reached 50% and the negative predictive value reached
100% for a CVI score of 3 (Table 4).
Discussion
The present authors believe this to be the first study to utilize a
non-invasive method, MRIF, to evaluate changes in portal vein
haemodynamic variables associated with oxaliplatin-based che-
motherapy for CRLM with or without SI. The present data dem-
onstrate that oxaliplatin-based chemotherapy is associated with
portal vein dilatation measured by MRIF. In patients who devel-
oped SI (CVI scores: 3), portal vein dilatation and a trend
towards a non-significant decrease in mean portal vein flow
velocity was observed, but no changes in portal vein flow were
seen.
The present MRIF findings are consistent with the proposed
model for SI effects after oxaliplatin-based treatment (Fig. 4).21
Portal vein dilatation alone and in combination with a trend
towards a change in mean flow velocity can be interpreted as an
indirect sign of higher liver parenchyma resistance to blood flow
in the sinusoids. Increased liver parenchyma resistance is usually
documented in cases of high-grade fibrosis and cirrhosis,23 which
were not observed in the present data, which supports the role of
SI in the changes observed in portal vein haemodynamics. The
present authors are unaware of any other reports of directly mea-
sured portal dilatation in association with oxaliplatin-based treat-
ment or SI. An increase in spleen size after oxaliplatin-based
chemotherapy20 as a consequence of SI16 may be regarded as an
indirect sign of congestion in the portal system (Fig. 4). This
reversible, oxaliplatin dose-dependent increase in splenic size is
also documented as one of the reasons for associated thrombocy-
topoenia,16,20 which directly influences the APRI value, another
predictor of SI.17,27 Cases of clinically manifested symptoms21,28
and liver vein wedge catheter-verified portal hypertension22 have
been reported after oxaliplatin-based chemotherapy induced SI.
The present findings support the hypothesis that oxaliplatin-
based treatment and subsequent SI lead to blood congestion in
the portal system. Portal haemodynamics are balanced in a
‘new’ steady state, maintaining equivalent liver perfusion with an
unchanged portal blood flow.
Recent clinical studies indicate that SI after oxaliplatin-based
chemotherapy in patients undergoing liver resection for CRLM is
associated with increased postoperative morbidity.9,11 The accu-
rate and sensitive non-invasive prediction of SI may change strat-
egies for the management of CRLM patients. Addition of MRIF
portal flow measurement to routine tumour response evaluation
may represent an affordable clinical tool with which to optimize
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Figure 2 Bagplot for mean portal flow velocity and cross-section
area. A bagplot is a bivariate generalization of the boxplot. For each
of the patient groups, the two-dimensional median (*) is approxi-
mated; the darker convex polygon, called the ‘bag’, contains 50% of
all points and the lighter convex hull contains all the points. Actual
values are shown as points on an ordinary scatterplot. Dotted lines
shows best performing threshold values for mean portal flow veloc-
ity (14.35 cm/s) and cross-section area (1.55 cm2) estimated by
receiver operating characteristic analysis
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the number of cycles of chemotherapy administered before liver
surgery and the timing of liver surgery after chemotherapy.
Several clinical studies have tried to identify predictive factors
associated with the development of SI after oxaliplatin-based
therapy. The duration of chemotherapy,9,11 age,29 female sex,11 pre-
operatively elevated AST,11 GGT,12,14 initial non-resectability and
synchronous metastases,14 tumour size of > 5 cm and positive
nodes with primary tumour12 are associated with a high risk for
the development of SI. The low sensitivities and specificities of
these variables make them less useful for SI prediction. However,
the APRI is a more sensitive and specific independent predictor of
SI caused by oxaliplatin-based chemotherapy.17 The APRI is also
reported to be a predictor of risk for oxaliplatin-induced sple-
nomegaly before chemotherapy is started.27 Various reports on
radiological methods utilizing superparamagnetic iron oxide-
enhanced T2 MRI in SI prediction show wide discrepancy in their
sensitivity and specificity results, which range from 87% and
89%,18 to 14% and 100%,15 to 75% and 100%30 for sensitivity and
specificity, respectively. Doppler ultrasonography can evaluate
portal flow haemodynamics, but interobserver variability and dif-
ferences in patient anatomy and investigational conditions may
cause non-reproducibility. Such drawbacks are eliminated by the
more objective MRIF23 used in the present study. Portal vein dila-
tation and changes in mean flow velocity as measured by MRIF
are sensitive indicators of SI, although they are less specific than
the methods mentioned earlier.
There are several limitations to the present study. By contrast
with other studies, the current study failed to show a direct asso-
ciationbetweenoxaliplatin-based treatment and SI,7,8 probably as a
result of its small sample size. However, this was not the aim of the
study. In the present study, all of the patients with SI had received
oxaliplatin-based chemotherapy, as they had in a large histopatho-
logical study conducted by Rubbia-Brandt et al.7 However, the
period between the end of oxaliplatin treatment and liver surgery
was relatively long in the present study (Table 2). It remains unclear
how long the SI effect lasts after chemotherapy, but it is probably
much longer than the commonly reported period of 5–6 weeks
after neoadjuvant treatment.An increase in spleen size of50% is
strongly correlated with the occurrence of SI and remains for
6 months after cessation of oxaliplatin.16 Ryan et al. observed CVI
scores of 3 in 11% of patients who did not receive any chemo-
therapy in the year prior to liver surgery, but did not describe their
patients’ past history of chemotherapy treatment.8 The analysis of
diagnostic efficacy using ROC curves can be perceived as another
drawback of the present study. Sensitivity and specificity values
estimated by ROC analysis should be interpreted according to the
terms of their confidence intervals, rather than as absolute values,
given the relatively small sample size (Table 4).
Surveillance byMRIF of changes in portal vein haemodynamics
is needed to be performed before, during and after oxaliplatin-
based chemotherapy. The dynamic of any such changes can verify
whether the onset of SI in the liver parenchyma is associated with
the lowering of mean portal flow velocity in the dilated portal
vein. The potential benefits of the method proposed should be
studied in other prospective clinical studies.
In conclusion, oxaliplatin-based chemotherapy for CRLM,with
orwithout SI, is associatedwithportal veindilatation. Inpatients in
Table 4 Receiver operating characteristic analysis results for predicting a combined vascular injury score of 3
Variable and threshold AUC
(95% CI)
Sensitivity
(95% CI)
Specificity
(95% CI)
PPV NPV
Cross-section area 1.55 cm2 0.775 (0.603–0.948) 100 (100–100) 65 (48–83) 43 100
Mean velocity 14.35 cm/s 0.815 (0.637–0.994) 100 (100–100) 52 (30–74) 35 100
Mean velocity 14.35 cm/s and
cross-section area 1.55 cm2
0.855 (0.718–0.993) 100 (100–100) 78 (61–96) 50 100
AUC, area under the receiver operating characteristic curve; 95% CI, 95% confidence interval; PPV, positive predictive value; NPV, negative predictive
value.
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Figure 3 Receiver operating characteristic (ROC) curve for sinusoi-
dal injury (defined as a combined vascular injury score of 3) pre-
diction utilizing the cross-section area and mean portal flow velocity
measured by magnetic resonance imaging flowmetry. Shading indi-
cates the 95% confidence interval of the ROC curve
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whom SI develops, portal vein dilatation, together with a
tendency towards a decreased mean portal flow velocity, was
observed as a marker of changes in portal vein haemodynamics,
whereas portal flow remained unchanged. This may indicate that
oxaliplatin-based chemotherapy and subsequent SI are associated
with an increase in liver parenchyma resistance to blood flow. The
evaluation of portal vein haemodynamics by MRIF can identify
patients without risk for SI with high accuracy in a non-invasive
manner.
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